

Section: [6. Anti-infective medicines](#) > [6.2. Antibacterials](#) > [6.2.1. Access group antibiotics](#)

		EMLc	ATC codes: <a href="#">J01DB01</a>
Indication	Bacterial infection of unspecified site	ICD11 code: <a href="#">1C81</a>	
INN	Cefalexin		
Medicine type	Chemical agent		
Antibiotic groups	<a href="#">A ACCESS</a>		
List type	Core (EML) (EMLc)		
Formulations	Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid (EMLc) ; 250 mg per 5 mL (anhydrous) powder for oral liquid (EMLc) Oral > Solid: 250 mg (as monohydrate) (EMLc)		
EML status history	First added in 2009 ( <a href="#">TRS 958</a> ) Removed in 2017 ( <a href="#">TRS 1006</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . <a href="#">↗</a>		
Wikipedia	<a href="#">Cefalexin</a> <a href="#">↗</a>		
DrugBank	<a href="#">Cefalexin (Cephalexin)</a> <a href="#">↗</a>		

### Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of antibacterials undertaken by the Expert Committee in 2017, listing of cefalexin was reviewed and specific indications for its use were recommended. Refer to the 2017 recommendation(s) for cefalexin for more information.

